Jump to main content
Jump to site search
Book cover

Kinase Drug Discovery: Modern Approaches Editors: Richard A Ward, Frederick W Goldberg


About this book

Kinase inhibition remains an area of significant interest, and growing importance, across academia and the pharmaceutical industry. There are now many marketed drugs that target kinases and a significant number of compounds are currently in various stages of clinical development. This book is a forward-looking analysis of a number of key areas for kinase inhibition in the coming years.

From the book series:
Drug Discovery

Book content

  • Introduction to Kinase Drug Discovery - Modern Approaches
  • New Screening Approaches for Kinases
  • The Screening and Design of Allosteric Kinase Inhibitors
  • Covalent Inhibition of Kinases
  • Small Molecule Macrocyclic Kinase Inhibitors
  • The Design of Brain Penetrant Kinase Inhibitors
  • Cutting Edge Approaches to Structure-based Computational Modelling of Kinases
  • The Properties of Kinase Inhibitors
  • Assessment and Optimization of Kinase Inhibitor Selectivity to Achieve Candidates with an Appropriate Safety Profile
  • Drugging the Kinome
  • The Importance of Kinase Mutations in Cancer Drug Discovery
  • Kinase Inhibition for Immuno-oncology
  • A Structural Perspective of the Pseudokinome: Defining the Targetable Space
  • The Future of Kinase Therapeutics

The print version of this book is planned for release on 08 November 2018. Information about this book is subject to change without notice.

Pre-order hardback £169.00 *
* Exclusive of taxes
This book contains 406 pages.

Publication details

Copyright year: 2019
Print ISBN: 978-1-78801-083-2
ePub eISBN: 978-1-78801-563-9
Citation:

Author information

Dr Richard A Ward is a Computational Chemist, Oncology iMed, at AstraZeneca, UK. He received his BSc (Hons) in Chemistry with Bio-organic Chemistry at The University of Birmingham and gained a PhD in Computational Chemistry also at The University of Birmingham, under the supervision of Dr John Wilkie. His experience is in target selection, lead identification, lead generation and lead optimisation against kinase and non-kinase targets with specialisations in fragment-based lead generation along with library design and collection enhancement activities. He has publications in lead generation, virtual screening, druggability assessments, collection enhancement activities using computational ring enumeration along with reagent enhancement and has published supporting papers with a biological focus. He is also named as an inventor on a number of small molecule patents. Dr Frederick W Goldberg is a Medicinal Chemist at AstraZeneca, UK. He received his MSci (Hons) in Natural Sciences (Chemistry) at Cambridge University and then gained a PhD in Organic Chemistry at Imperial College, London, under the supervision of Dr Alan Armstrong. Subsequently he completed a Postdoc (AstraZeneca Fulbright scholarship) at the University of Texas at Austin, USA on "Formal synthesis of Diazonamide A", under the supervision of Dr Philip Magnus. He is presently a lead chemist on various kinase and non-kinase targets, working within the oncology lead generation group and diabetes lead optimization groups. He has publications in kinase lead generation and has filed 8 patents as primary inventor.